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Abstract: A spectrophotometric method was developed for simultaneous determination of amlodipine (Aml) and valsartan (Val)   without 
previous separation. In this method amlodipine in methanolic solution was determined using zero order UV spectrophotometry by 
  measuring its absorbency at 360.5 nm without any interference from valsartan.
Valsartan spectrum in zero order is totally overlapped with that of amlodipine. First, second and third derivative could not resolve the 
overlapped peaks.
The first derivative of the ratio spectra technique was applied for the measurement of valsartan. The ratio spectrum was obtained by 
dividing the absorption spectrum of the mixture by that of amlodipine, so that the concentration of valsartan could be determined from the 
first derivative of the ratio spectrum at 290 nm. Quantification limits of amlodipine and valsartan were 10–80 µg/ml and 20–180 µg/ml 
respectively. The method was successfully applied for the quantitative determination of both drugs in bulk powder and pharmaceutical 
formulation.
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Introduction
Amlodipine  is  a  dihydropyridine  calcium  channel 
blocker. It is used for management of hypertension 
and angina pectoris.1 Several methods were developed 
for  amlodipine  determination.  The  most  recent 
reported  methods  include  capillary  electrophoresis 
(CE)  methods  which  were  used  for  amlodipine 
determination2–4  or  for  enantiomer  separation  and 
determination of amlodipine.5–7
HPLC methods were used for the determination of 
amoldipine alone either in human fluids or in tablet 
form.8–15 Other HPLC methods determine amlodipine in 
a mixture with another drug as metoprolol succinate,16,17 
atrovastatin,18,19  benazepril20,21  and  losartan.22  Amlodipine 
was determined in tablets and biological fluids using 
voltametric  method.23  Spectrophotometric  methods 
were  used  for  the  determination  of  amlodipine,24,25 
amlodipine,  enalapril  mixture26  or  for  monitoring 
amlodipine photodegradation.27
Valsartan is an angiotensin II receptor antagonist 
used in the management of hypertension to reduce 
cardiovascular mortality in patients with left ventric-
ular dysfunction following myocardial infarction and 
heart failure.1
Several methods have been reported for valsartan 
assay including HPLC methods,28–32 spectrofluorimetric 
method33 and capillary electrophoresis.34
Valsartan and hydrochlorothiazide mixture were 
determined  using  HPLC  methods,35–37  derivative 
spectrophotometric methods,38–40 TLC method41 and 
CE method.42
Two  HPLC  methods  for  the  determination  of 
  valsartan and nebivolol were reported.43,44
Simultaneous  determination  of  valsartan  and 
amlodipine in post mortem whole blood was carried 
out using HPLC-MS technique.45
The goal of antihypertensive therapy is to abolish the 
risks associated with blood pressure elevation without 
adversely  affecting  quality  of  life.  Drug  selection 
is based on efficacy in lowering blood pressure and 
in  reducing  cardiovascular  end  points  including 
stroke, myocardial infarction and heart failure. The 
American Society of Hypertension presents a paper 
on  combination  therapy  of  hypertension.  Specific 
combinations are designated as preferred or acceptable, 
less  effective  combinations  are  also  identified. The 
study classifies the combination therapy of amlodipine 
and valsartan as acceptable.46
experimental
Chemicals and reagents
•	 Amlodipine  and  valsartan  donated  by  Novartis, 
Egypt.
•	 Exforge  tablets  labeled  to  contain  10  mg  of 
amlpdipine and 160 mg of valsartan. Batch number 
0051, manufactured by Novartis, Egypt.
•	 Methanol analytical grade (Analar).
Apparatus
•	 Ultraviolet / Visible spectrophotometer, Shimadzu, 
Japan 1601pc.
•	 Ultrasonic crest model 575T Cortland, New York 
13045, USA.
sample preparation
Stock  methanolic  solution  of  amlodipine  and 
  valsartan of concentration 100 µg/ml and 200 µg/ml 
respectively were separately prepared by dissolving 
the appropriate amount of the respective substance in 
methanol. Working standard solutions used for method 
optimization were prepared freshly before application 
by  mixing  suitable  aliquots  of  stock  solutions  of 
amlodipine and valsartan and diluted with methanol 
to obtain the required concentration ranges.
Stock methanolic solution of laboratory prepared 
mixture  of  amlodipine  and  valsartan  containing 
100 µg/ml and 1.6 mg/ml respectively was prepared 
by dissolving 25 mg amlodipine and 400 mg valsartan 
in 250 ml methanol.
Tablets working solution was prepared by dissolving 
an accurately weighed quantity of powdered exforge 
tablets  sample  containing  an  equivalent  of  10  mg 
amlodipine and 160 mg valsartan was transferred into 
100 ml volumetric flask, then 70 ml methanol was 
added. The mixture was sonicated for ten minutes 
and the volume was made up using methanol, then 
the sample was filtered.
procedure
Aliquots  (1–8  ml)  or  (1–9  ml)  of  amlodipine  or 
valsartan stock solutions respectively were transferred 
into two separate series of 10 ml volumetric flasks 
and  volumes  were  made  up  with  methanol.  The 
absorbance  spectrum  of  each  flask  were  recorded 
at zero order between 200–450 nm and stored in a 
personal computer.Simultaneous determination of Aml and Val
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The absorbance of amlodipine series were deter-
mined in zero order at 360.5 nm.
The UV absorption spectra of the series of   valsartan 
solutions  were  divided  wavelength  by  wavelength 
by a standard spectrum of amlodipine (40 µg/ml). 
The first derivative of the obtained ratio spectra with 
∆λ = 4 nm and scaling factor equal 10 were used for 
determination  of  valsartan  concentration  from  the 
amplitude at 290 nm.
Application of the Method  
for the Determination of Laboratory  
prepared Mixture
The  method  was  applied  for  the  determination  of 
laboratory  prepared  mixture  of  amlodipine  and 
valsartan  containing  100  µg/ml  and  1.6  mg/ml 
respectively. Aliquots (1–8 ml) and (1.5–10 ml) of 
the stock methanolic solution of laboratory prepared 
mixture were transferred into two separate series of 
10 ml and 100 ml volumetric flasks, volumes were 
made up using methanol. The first series of (10 ml) 
volumetric flasks was used for the determination of 
amlodipine, while the other series (100 ml volumetric 
flasks) was used for the determination of valsartan 
applying the same mentioned procedure.
Application of the Method for the 
Determination of exforge tablets
Aliquots of 1.5, 4 and 8 ml of tablets working solution 
were transferred into two separate series of 10 ml 
and 100 ml volumetric flasks for determination of 
amlodipine and valsartan respectively.
To study the accuracy of the proposed method and 
check the interference from excipients present in the 
dosage form, recovery experiment were carried out by 
standard addition method. This study was performed by 
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Figure 1. Amlodipine (1) and valsartan (2) structure formula.
2.500
2.000
1.500
1.000
0.500
0.000
200.0
2
1
250.0 300.0 350.0 400.0
Wavelength (nm.)
450.0
A
b
s
Figure  2.  UV  spectrophotometric  spectrum  of  methanolic  solution  of 
(1) amlodipine (45 µg/ml) and (2) valsartan (60 µg/ml).
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Figure 3. First derivative of ratio spectra of different concentrations of val-
sartan using spectrum of amlodipine (40 µg/ml) as a divisor spectrum.
Table 1. Analytical parameters from calibration graph in 
quantification of amlodipine and valsartan by the proposed 
method.
Regression data Amlodipine Valsartan
Linearity 10–80 µg/ml 20–180 µg/ml
Slope 0.011 0.086
Intercept 0.003 0.101
r (correlation coefficient) 0.9996 0.9997
r2 (coefficient of  
determination)
0.999 0.999
LOD (limit of detection) 5.5 µg/ml 8 µg/ml
LOQ (limit of quantitation) 8.5 µg/ml 12 µg/ml
Table 2. results of quantitative analysis of amlodipine and 
valsartan in bulk powder by the proposed method.
Taken Found % recovery
Aml* Val** Aml Val Aml Val
10 20 10.09 20.01 100.90 100.55
25 40 24.88 40.12 99.5 100.30
45 80 45.16 79.32 100.35 99.15
65 140 65.59 139.52 100.90 99.66
75 180 74.48 179.84 99.30 99.88
M ±	SD 100.19 ± 0.76 99.91 ± 0.55
notes: *Aml = amlodipine; **Val = valsartan.Mohamed
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Table 3. results of quantitative analysis of amlodipine and valsartan in laboratory prepared mixture by the proposed method.
Taken concentration of   
each drug in mixture
Found % recovery
Aml Val Aml Val
Aml Val
15 24 14.90 23.89 99.33 99.55
20 32 20.22 32.27 101.10 100.84
40 64 39.94 64.64 99.85 101.00
60 96 60.53 95.22 100.88 99.19
80 128 79.55 129.16 99.44 100.90
M ± SD 100.12 ± 0.820 100.30 ± 0.857
Table 4. results of quantitative analysis of amlodipine and valsartan in laboratory prepared mixture by the proposed 
method three times within the same day (repeatability).
Taken Found standard 
deviation Aml Val Aml Val
1st 2nd 3rd 1st 2nd 3rd Aml Val
30 48 30.8 30.42 29.17 47.66 47.17 48.36 0.85 0.62
50 80 50.25 49.98 49.38 80.15 80.62 79.13 0.45 0.76
65 104 63.97 65.54 64.76 104.90 103.98 103.74 0.78 0.61
80 128 80.14 79.85 80.62 127.92 128.56 128.60 0.39 0.38
Table 5. results of quantitative analysis of amlodipine and valsartan in laboratory prepared mixture by the proposed 
method over three different days (reproducibility).
Taken Found standard 
deviation Aml Val Aml Val
1st  
day
2nd  
day
3rd  
day
1st  
day
2nd  
day
3rd  
day
Aml Val
30 48 29.57 30.43 29.00 49.31 47.86 48.52 0.72 0.73
50 80 49.66 49.13 50.51 80.39 81.45 79.72 0.67 0.87
65 104 65.55 66.05 64.74 105.37 103.87 104.68 0.66 0.75
80 128 79.69 79.22 80.85 129.10 127.98 128.66 0.84 0.56
Table 6. results of quantitative analysis of amlodipine and 
valsartan in exforge tablets by the proposed method.
Taken Found % recovery
Aml Val Aml Val Aml Val
15 24 14.95 24.36 99.66 101.5
40 64 39.58 63.57 98.95 99.33
80 128 80.88 129.1 101.10 100.86
M ± SD 99.9 ± 1.1 100.56 ± 1.1
addition of different amounts of amlodipine and valsar-
tan to a known concentration of the commercial tablets.
Result and Discussion
The UV spectra of amlodipine and valsartan in zero 
order show that amlodipine has a significant peak 
at  360.5  nm  at  which  the  spectrum  of  valsartan 
does not interfere (Fig. 2). So methanolic   solution Simultaneous determination of Aml and Val
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Table 7. results for the application of the standard addition technique for the determination of amlodipine and valsartan in 
exforge tablets by the proposed method.
Taken from 
tablets (μg/ml)
Found of 
tablets
Added standard 
(μg/ml)
Found of added 
standard (μg/ml)
% recovery of added  
standard
Aml Val Aml Val Aml Val Aml Val Aml Val
 
15
 
24
14.95 24.36 25 40 25.21 39.58 100.85 98.94
45 72 45.45 72.56 101.00 100.78
65 104 64.72 103.82 99.57 99.83
 
40
 
64
39.58 63.57 15 24 15.08 24.13 100.53 100.54
20 32 20.08 32.36 100.38 101.12
35 56 34.74 55.81 99.26 99.66
M ± SD 100.27 ± 0.70 100.15 ± 0.81
of    amlodipine  was  quantitatively  determined  at 
360.5  nm,  Beer’s  law  was  obeyed  over  concen-
tration  range  10–80  µg/ml. The  amlodipine  con-
centration could be calculated using the following 
equation.
A = 0.011C + 0.003
Valsartan spectrum in zero order shows a com-
plete overlapping with that of amlodipine (Fig. 2). 
  Applying first, second and third order spectra did not 
resolve valsartan peaks. So first derivative of the ratio 
  spectra was applied to determine valsartan in pres-
ence of amlodipine.
The influence of ∆λ and the effect of the   divisor 
concentration on the calibration graph for the   proposed 
mixture was studied in order to select the best factor 
for the determination. Results indicate that ∆λ = 4 
was the most suitable one, while divisor   concentration 
range 10–60 µg/ml gave good results, 40 µg/ml was 
used overall.
For the determination of valsartan the absorption 
spectra of valsartan was divided by that of standard 
amlodipine solution (40 µg/ml). The first derivative 
of the developed ratio spectra were calculated with 
∆λ = 4 and scaling factor equal 10. (Fig. 3) shows 
that valsartan could be determined by measuring the 
amplitude at 290 nm.
The proposed method is applicable over the concen-
tration range 20–180 µg/ml. Valsartan concentrations 
could be determined applying the following equation.
A = 0.086C + 0.101
Parameters of regression equations of both drugs 
are collected in Table 1.
Accuracy  of  the  method  was  tested  and  results 
show M ± SD of 100.19 ± 0.76 and 99.91 ± 0.55 for 
amlodipine and valsartan respectively, (Table 2).
In order to demonstrate the validity and applica-
bility of the proposed method, recovery studies were 
performed by analysing laboratory prepared mixture 
of amlodipine and valsartan with different composi-
tion ratio (Table 3).
Results of the tested samples within day (repeat-
ability)  and  between  days  (reproducibility)  show 
standard deviation between results less than one indi-
cating high degree of precision (Tables 4 and 5).
The proposed method can be conveniently used to 
determine both amlodipine and valsartan in exforge 
tablets (Table 6).
The validity of the method was assessed by apply-
ing the standard addition technique for the determi-
nation of exforge tablets, good results were obtained 
(Table 7).
conclusion
In this study a new spectrophotometric method was 
developed  to  identify  amlodipine  and  valsartan  in 
mixture  without  previous  separation.  The  method 
was optimized and validated. The method was suc-
cessfully applied for the determination of amlodipine 
and valsartan in exforge tablets.
This method can yield results in a short time and 
does not require relatively expensive apparatus like 
HPLC.
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